Percutaneous pulmonary valve implantation helps in prolonging the lifespan of surgically placed right ventricleto-pulmonary artery (RV-PA) conduits, and represents a less invasive alternative to repeat open-heart surgery. The clinical indications for treatment match those of surgery. As far as the suitability is concerned, the current ideal substrate is a degenerated RV-PA conduit, because of the presence of a certain degree of calcification that offers a safe anchoring point. So far, patients have been treated with low morbidity and mortality that were further improved with increasing experience. After percutaneous pulmonary valve implantation, patients experience a subjective improvement, mirrored by an objective increase of measured exercise capacity parameters and by reduced RV-PA gradient, regurgitant fraction, and RV volumes. New developments in the experimental field should result in an extension of indications in the future.
Background
The number of patients requiring reintervention for right ventricular outflow tract (RVOT) dysfunction after repair of complex congenital heart disease is increasing. This is a result of improved survival after early surgery, combined with growing awareness of the detrimental long-term effects of pulmonary regurgitation and RVOT obstruction on exercise tolerance, right ventricular function and arrhythmia susceptibility [1] [2] [3] [4] . Although there is an increasing inclination to intervene at an earlier stage to preserve right ventricular function [5] , the limited longevity of surgically placed conduits has restricted this strategy as it commits patients to numerous reoperations each with increasing risk. The recent availability of a percutaneous approach to treat RVOT dysfunction promises, therefore, an attractive solution, as it permits earlier intervention without the problems associated with surgery and cardiopulmonary bypass.
The device and procedure
The percutaneous pulmonary valve (PPV) device is composed of a bovine jugular venous valve sutured inside a platinum iridium stent (NuMED Inc., Hopkinton, New York, USA; Fig. 1 ). It is mounted on a specially designed front-loading delivery system comprising a balloon in balloon catheter system (NuMED) and is delivered to the RVOT through the venous circulation, usually from a femoral approach. The procedure is performed under general anaesthesia with the guidance of biplane angiography (Fig. 2) . Haemodynamic assessment and angiography are performed before and after device deployment and procedure time is in the range of 1-2 h.
The large coaptation surface of the leaflets of the bovine jugular venous valve means that the device is functional at a variety of different diameters. However, the largest outflow tract that can be treated with the current device is 22 mm. The limitation is imposed by the maximal size of the biologically available valve; expansion beyond this diameter is likely to lead to incompetence.
Clinical experience
The first PPV was implanted by us in 1999 in a lamb model, confirming feasibility of this new approach [6] . Subsequently, PPV implantation (PPVI) has been performed in humans, with the clinical programme starting at the Hôpital Necker Enfants Malades (Paris, France) and continuing at Great Ormond Street Hospital for Children and The Heart Hospital (London, UK). The index case reported a successful outcome in a 12-year-old boy, with pulmonary atresia, who had significant stenosis and regurgitation of his right ventricle-to-pulmonary artery The percutaneous pulmonary valve device is composed of a bovine jugular venous valve sutured inside a platinum iridium stent.
conduit (18 mm, Carpentier-Edward). There were no complications after 1 month, with complete resolution of the pulmonary regurgitation and partial relief of the obstruction [7] . After this first implant, further patient series have been reported [8, 9] .
The first 59 patients, who represent the largest published series, demonstrated an acute clinical improvement after PPVI, with New York Heart Association functional class falling from a median of 2 to 1 (P < 0.001) and an increase in objective exercise capacity (VO 2max : from 26 ± 7 to 29 ± 6 ml/kg/min, P = 0.006). RVOT gradient fell after PPVI [from 63 ± 23 to 40 ± 18 mmHg (P < 0.001)]; this result was maintained at latest follow-up (9.8 ± 1.4 months). Magnetic resonance imaging showed significant reduction in pulmonary regurgitant fraction (from 21 ± 13 to 3 ± 4%, P < 0.001) and right ventricular end-diastolic volume (94 ± 28 to 82 ± 24 ml/beat/min, P < 0.001). To date, PPVI has been performed in over 200 patients at our centre, with the majority having an original diagnosis of tetralogy of Fallot often with pulmonary atresia and predominantly presenting with dysfunctional right ventricle-to-pulmonary artery conduits.
Although PPVI compares favourably with surgical valve replacement [10] , we have experienced a number of complications that have contributed to our 'learning curve' and informed subsequent practice. Importantly, failure of PPVI does not preclude a successful surgical approach. Procedural complications have included device instability (two patients), homograft rupture (three patients), coronary artery compression (one patient), obstruction of a right pulmonary artery (one patient) and rupture of a left pulmonary artery (one patient). In the follow-up, the 'hammock effect', a cause of in-stent stenosis because of passage of blood between the device and the recipient outflow tract, and stent fractures have been the main issues. The 'hammock effect' has now been resolved by a change in device design while stent fractures, an expected finding, usually without clinical consequence, can be anticipated with careful radiograph follow-up and are treated effectively with repeated PPVI. Finally, endocarditis and haemolysis have also been described but greater experience is required before the true prevalence becomes apparent. In the follow-up, we have experienced seven deaths. Two patients presented in cardiogenic shock before the procedure, but despite technically successful valve implantations, the patients died from their comorbidities early after the procedure. Five patients died during the extended followup (two sudden deaths presumed because of arrhythmia, one sepsis and two patients with cardiac failure secondary to chronic pulmonary hypertension).
Indications
Clinical indications for PPVI, in general, have mirrored those used in the surgical setting. These include the presence of significant RVOT dysfunction with progressive right ventricular dilatation or dysfunction, impairment of exercise tolerance and arrhythmias [11] . However, we have also performed this procedure for patients who would not conventionally be considered for surgery on account of risk, including those with severe chest deformity, with pulmonary vascular disease and patients 'in extremis'. The less invasive nature of PPVI can offer clinical benefit, particularly in the first two categories of patients that would not otherwise be available. At present, patients weighing less than 15-20 kg cannot be treated with this approach because of the necessary size of the delivery system (22 French) for device delivery.
In our experience, degenerated homografts represent the best substrate for anchoring the valved stent because of their tendency to calcify circumferentially. Native outflow tracts, particularly if enlarged with a patch, do not generally represent a secure environment for deployment of a valved stent. Eligibility for PPVI depends strongly on the morphology of the outflow tract. Assessment is based on a detailed knowledge of the surgical history, three-dimensional imaging using either gadolinium contrast magnetic resonance angiography or, if contraindicated, contrast-enhanced computed tomography. If outflow tracts are considered borderline, in terms of size and shape, balloon sizing is carried out at the time of catheterization before making a final decision to proceed to implantation. Advance knowledge of the anatomy of the coronary circulation relative to the proposed implantation site is mandatory.
Clinical and physiological consequences of percutaneous pulmonary valve implantation
Although PPVI provides an important new clinical treatment, it also creates a unique situation to study the potential for right ventricular recovery after the Percutaneous pulmonary valve mounted on a specially designed front-loading delivery system comprising a balloon in balloon catheter system. treatment of outflow tract dysfunction, as it is not confounded by the effect of cardiopulmonary bypass-like surgery. We recently reported the acute effects of relieving right ventricular obstruction [12] . In contrast, to popular belief, it was found that right ventricular obstruction is in fact poorly tolerated by the right ventricle and that relief resulted in a reduction in right ventricular volumes, an increase in stroke volume, better left ventricular filling and ejection, and an objective improvement in exercise capacity. Further investigation is required to understand the acute effects of relieving right ventricular volume overload and also to quantify the potential for myocardial remodelling in the longer term.
Cost-effectiveness
With increasing pressure on healthcare resources the cost-effectiveness of new techniques such as PPVI has important implications for clinical practice. We developed a model that compared our PPVI experience with a contemporary surgical population. PPVI proved cheaper than surgery because of reduced hospital stay and fewer complications, despite a higher likelihood of reintervention during follow-up. In addition, because of lower mortality, it proved more effective. Greater costeffectiveness in this model therefore allowed scope for variation in our assumptions. Importantly, reintervention could reach up to 17% per year before incremental cost-effectiveness would be lost, indicating that PPVI durability does not need to match that of surgically implanted valves from an economic point of view [13] .
Future developments
At present, PPVI is restricted to patients with outflow tracts less than 22 mm in diameter. The majority of patients with an indication for intervention, however, has dilated outflow tracts and is therefore unsuitable for this approach. Experimental work is underway to address percutaneous valve replacement in these larger RVOTs. One development has been the development of a selfexpandable stent that allows downsizing of the diameter of the RVOT to the biologically available valve size; the main limitation is, however, the frequently tortuous pulmonary anatomy that may affect correct stent deployment [14] . A second alternative that has been proposed is a hybrid approach, involving cooperation between surgeons and interventionalists. By a left thoracotomy the RVOT is banded, using two radioopaque rings, and subsequently the valved stent is implanted percutaneously or by a transventricular approach. This avoids cardiopulmonary bypass while ensuring a stable valve position [15] . An alternative strategy that we have also contemplated is the implantation of an expandable conduit, at the time of initial repair, which could be dilated as the child grows and subsequently treated with a percutaneous valve when dysfunction develops [16] . These studies still remain experimental, having been performed only in animal models where the anatomy of the native RVOT is more favourable than in patients with previous surgery.
Summary
PPVI is a minimally invasive technique that can be performed with low morbidity and mortality, prolonging conduit life and delaying or avoiding the need for repeat surgery. At present, it is not suitable for all patients, in view of morphological criteria, but new developments in the experimental field should result in an extension of indications in the future.
